Ocular Therapeutix Inc. Stock
€7.35
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Ocular
sharewise wants to provide you with the best news and tools for Ocular, so we directly link to the best financial data sources.
Financials
News
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
According to the SEC filing dated May 15, Acuta Capital Partners, LLC disclosed a first-quarter sale of 460,887 shares of Ocular Therapeutix (NASDAQ:OCUL).
Ocular Therapeutix is a biopharmaceutical
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
On May 15, 2026, Saturn V Capital Management disclosed a full exit from Ocular Therapeutix (NASDAQ:OCUL), selling 1,504,880 shares in a trade estimated at $14.34 million based on quarterly average
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down
On February 17, 2026, VR Adviser, LLC disclosed in a U.S. Securities and Exchange Commission filing that it sold 5,845,915 shares of Ocular Therapeutix (NASDAQ:OCUL), an estimated $71.01 million